Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Prevnar
Synonyms :
pneumococcal 7-valent vaccine
Class :
Bacterial vaccines
Brand Name :
Prevnar
Synonyms :
pneumococcal 7-valent vaccine
Class :
Bacterial vaccines
Not indicatedÂ
Indicated for pneumococcal disease prophylaxis
Age 2 month-6 month: Administer 0.5 ml intramuscularly; give each three doses for eight weeks, which is continued with a fourth dose administered between 12-15 months
Age 7 month-12 month: Administer 0.5 mL intramuscularly with a minimum of four weeks between the first and second doses, continued by a third dose at the age of one year, with an eight-week gap between the second and third doses Individuals who have previously been administered 1-2 doses of the conjugate vaccine but have not completed the full regimen should be administered with a 0.5 mL intramuscular (IM) injection, continued by an additional dose after a minimum of eight weeks when they reach the age of 12-15 months
Age 1 year-2 years: Administer 0.5 mL intramuscularly with a minimum interval of eight weeks between doses Individuals who were administered a single vaccine dose prior to reaching the age of twelve months but have not yet finished the full vaccination regimen should be administered a 0.5 mL dose, continued by a second dose with a minimum of eight weeks Individuals who have earlier been administered two doses of the vaccine before reaching age of twelve months should be administered a 0.5 mL dose after a minimum of eight weeks have passed since their most recent vaccination
Age 2 years-5 years: Administering 0.5 mL as one dosage is recommended for patients who have initiated the vaccination process but experienced a lapse, a 0.5 mL one dose is advised in that case Individuals suffering from chronic illnesses or those with weakened immune systems the recommended dosage consists of two administrations, each with 0.5 ml with an interval of no less than eight weeks between them
Children with sickle cell/HIV infection, asplenia/immunocompromised/chronic illness: Administer 0.5 mL intramuscularly (IM) in two separate doses, with a minimum interval of at least eight weeks between each dose
Polysaccharide Vaccine: Age 2 years: Administer 0.5 ml subcutaneously or intramuscularly earlier vaccinated with pneumococcal conjugate vaccine: Immunocompromised patients/sickle cell anemia/HIV/aplasia:
Inject 0.5 mL either intramuscularly (IM) or subcutaneously A follow-up vaccination is recommended after a period exceeding 5 years, and it should not be administered within a span of less than three years
chronic illness patients: Administer 0.5 mL via intramuscular (IM) or subcutaneous injection Revaccination is not advised Following transplant of bone marrow:
Administer 0.5 mL via intramuscular (IM) or subcutaneous injection at the twelve & twenty four month intervals post-transplantation
Refer adult dosingÂ
Actions and Spectrum:Â
Immunization: The vaccine contains antigens from seven different serotypes of streptococcus pneumoniae. When administered, it stimulates the recipient’s immune system to produce antibodies against these serotypes.Â
Antibody Production: Following vaccination, the immune system produces distinct antibodies capable of identifying and counteracting the bacterial variants encompassed within the immunization.Â
Frequency not defined Â
Unusual tiredness or weaknessÂ
Appetite lossÂ
DrowsinessÂ
RashÂ
Back painÂ
DizzinessÂ
HeadacheÂ
Black Box Warning:Â Â
None Â
Contraindication/Caution:Â Â
Severe Allergic Reaction (Anaphylaxis): If an individual has a known severe allergy to any component of the vaccine, such as diphtheria toxoid, aluminum, or other ingredients, it is contraindicated.Â
Moderate to Severe Illness: It is generally recommended to postpone vaccination in individuals with moderate to severe acute illnesses until they have recovered.Â
Pregnancy: pneumococcal 7-valent vaccine is typically not recommended for pregnant individuals unless the potential benefits outweigh the risks, as there may not be enough safety data in this population.Â
Immunocompromised individuals: In certain cases, individuals with severe immunodeficiency or those receiving immunosuppressive therapy may not be candidates for vaccination with pneumococcal 7-valent vaccine. However, this decision should be made on a case-by-case basis, and consultation with a healthcare provider is crucial.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: The pneumococcal 7-valent vaccine, also known as PCV7, is a vaccine that protects Streptococcus pneumoniae.Â
Pharmacodynamics:Â Â
The vaccine functions by inducing an immunological response in the body that produces antibodies directed against the capsular polysaccharides it contains. These antibodies are specific to the polysaccharides and are aimed at neutralizing the bacterium. Â
Pharmacokinetics:Â
N/AÂ
Administration: Â
pneumococcal 7-valent vaccine is administered as an intramuscular injection. It is typically given in the thigh for infants and young children or in the upper arm for older children and adults.Â
Patient information leafletÂ
Generic Name: pneumococcal 7-valent vaccineÂ
Why do we use pneumococcal 7-valent vaccine? Â
pneumococcal 7-valent vaccine is primarily used to prevent pneumococcal infections, which can lead to a range of illnesses, including pneumonia, meningitis, sepsis, and otitis media (ear infections). These infections can be particularly severe in young children and the elderly.Â
pneumococcal 7-valent vaccine is commonly administered to infants and young children as part of their routine vaccination schedule. It helps protect them from pneumococcal severe diseases, reducing the risk of hospitalization and death.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
